<DOC>
	<DOCNO>NCT00378716</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug way kill tumor cell . PURPOSE : Randomized phase III trial determine effectiveness uracil , tegafur , leucovorin compare fluorouracil plus leucovorin patient resect stage II stage III colon cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Resected Colon Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare relative efficacy oral uracil/tegafur ( UFT ) leucovorin ( CF ) vs. fluorouracil ( 5-FU ) CF prolong overall disease-free survival patient potentially curatively resected stage II/III adenocarcinoma colon . II . Compare prognostic significance several biomarkers alone combination , include DNA mismatch repair gene mutation , p53 , delete colon cancer gene , proliferation status , thymidylate synthase , patient treat UFT/CF vs. 5-FU/CF . III . Evaluate relationships various biomarkers association patient tumor characteristic . IV . Compare quality life patient treat UFT/CF vs. 5-FU/CF . OUTLINE : This randomize study . Patients stratify number positive lymph node participate institution . For quality-of-life portion study , patient stratify age , sex , ethnicity . Treatment begin within 6 week curative resection within 1 week randomization . Patients randomly assign one two group . The first group receive intravenous leucovorin follow intravenous fluorouracil weekly 6 week . Treatment repeat every 8 week total 3 course . The second group receive oral uracil/tegafur , oral leucovorin every 8 hour 28 day . Treatment repeat every 5 week total 5 course . No concurrent halogenated antiviral agent ( e.g. , sorivudine ) permit . After complete treatment , patient complete quality-of-life questionnaire one year . PROJECTED ACCRUAL : Approximately 1,500 patient enter 3 year provide 1,452 evaluable patient .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon curatively resect within 42 day prior entry , follow : Stage II ( T34 N0 M0 , Modified AstlerColler B2/3 ) , i.e. , tumor invasion wall colon extension pericolonic tissue Stage III ( T N13 M0 ) , i.e. , tumor invasion depth No sarcoma , lymphoma , carcinoid histology No laparoscopically assist colectomy unless perform protocol NCCTG934653 ( intergroup study INT0146 ) Entire tumor locate peritoneal reflection surgical exploration 15 cm anal verge endoscopy Involved adjacent structure ( e.g. , bladder , small intestine , ovary ) remove en bloc histologically negative margin More 1 synchronous primary colon tumor allow Most advanced tumor use stage assignment No previous synchronous rectal cancer Intestinal obstruction allow Preliminary complementary colostomy allow Walledoff perforation allow No free perforation , i.e. , free air fluid abdomen No prior invasive colon rectal malignancy regardless diseasefree interval PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : At least 10 year ( exclude cancer diagnosis ) Hematopoietic : WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal AST ALT normal Renal : Creatinine normal Cardiovascular : No active ischemic heart disease No NYHA class III/IV status No myocardial infarction within 6 month No symptomatic arrhythmia within 6 month Other : No nonmalignant systemic disease precludes protocol treatment No psychiatric addictive disorder precludes inform consent No second malignancy within 10 year except : Effectively treat nonmelanomatous skin cancer Surgically cure carcinoma situ cervix Lobular carcinoma situ breast No pregnant woman Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
</DOC>